



16 August 2023

ASX ANNOUNCEMENT

Statement from independent non-executive director Dr Michael Seiden

The Company attaches a statement received from independent, non-executive director Dr Michael Seiden in response to the receipt of the Notice under section 249D of the *Corporations Act 2001* (Cth).

Authorised for release by Dr Michael Seiden, director of ImpediMed Limited.

Contact Details

Investor Relations Contact:

Hannah Howlett

WE Communications

T: +61 450 648 064

E: hhowlett@we-worldwide.com

E: investorrelations@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Response to Notice 249D from Non-Executive Director Michael Seiden, MD.

As a Non-Executive Director of ImpediMed not subject to the current 249D Notice by a small group of shareholders,¹ I am stating my full and categorical support for the existing Board of ImpediMed.

While my tenure on the ImpediMed has been short, I am urging shareholders to vote **against** all eight proposed resolutions:

- four resolutions are proposed for the removal of each of Don Williams, Amit Patel, David Anderson, and Daniel Sharp as directors of the Company; and
- four resolutions are proposed for the appointment of each of McGregor Grant, Christine Emmanuel-Donnelly, Andrew Grant, and Janelle Delaney as directors of the Company.

As a US trained medical oncologist and healthcare executive I fully endorse and believe in the current strategy of the Company's existing Board and management team. This is focused on rapidly scaling the market access and go-to-market team to leverage the opportunity BIS and specifically SOZO, offers in the evaluation of lymphoedema with a specific focus on the US healthcare facilities caring for the large population of women with breast cancer.

My decision to join the ImpediMed Board was equally informed by the substantial opportunity to build a company to significant scale able to address a gap in the market, the relevance of my experience to contribute to the ambitions of ImpediMed, and the quality of the existing Directors on the Board.

I believe the proposal by a minority group of requisitioning shareholders will be extraordinarily disruptive, risks derailing a well-thought through strategy, and creates challenges in recruiting a high-calibre US based Chief Commercial Officer and Chief Medical Officer at a time where speed to execution is vital.

I believe maximizing shareholder value is best achieved by voting **against** all eight resolutions.

Yours sincerely

Michael Seiden MD PhD
Non-Executive Director

¹ See ImpediMed's ASX release dated 3 August 2023 for further details.